1620 Investment Advisors, Inc. Neurocrine Biosciences Inc Transaction History
1620 Investment Advisors, Inc.
- $126 Million
- Q4 2024
A detailed history of 1620 Investment Advisors, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, 1620 Investment Advisors, Inc. holds 933 shares of NBIX stock, worth $106,334. This represents 0.1% of its overall portfolio holdings.
Number of Shares
933
Previous 867
7.61%
Holding current value
$106,334
Previous $99,000
28.28%
% of portfolio
0.1%
Previous 0.08%
Shares
3 transactions
Others Institutions Holding NBIX
# of Institutions
652Shares Held
96.5MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.62 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.15 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$557 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$344 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$289 Million0.06% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $10.9B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...